Prescribing extended adjuvant letrozole

摘要: The efficacy of 5 years adjuvant tamoxifen in preventing disease recurrence patients with breast cancer has been well established. Once have completed therapy, however, risk remains but treatment options are limited. Aromatase inhibitors such as letrozole emerging potential alternatives to therapy and an option after tamoxifen. pioneering MA-17 trial was designed evaluate the safety extended setting postmenopausal women who remained disease-free about unblinded at first interim analysis proved more effective than placebo improving survival. As such, optimal duration left question. However, recent results from cohort shown ongoing increasing benefit for up 4 tamoxifen, suggesting that longer periods safe clinically beneficial.